Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy

• Sponsor: National Heart, Lung, and Blood Institute (NHLBI) (NIH)
• Overall Status: Completed
• CT.gov ID: NCT00433745
• Collaborator: (none)
• Enrollment: 4
• Location: 1
• Arm: 1
• Duration (Months): 33
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

This study will determine the safety and effectiveness of an experimental vaccine in controlling the abnormal growth of cells in patients with myelodysplastic syndrome (MDS, also known as myelodysplasia), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML). It will test whether the vaccine can increase the number of immune cells responding to the cancer and thereby slow progression of the illness, improve blood counts, reduce the need for transfusions of blood and platelets, or even achieve a disease remission. The vaccine contains part of a protein that is produced in large amounts by cells of patients with these cancers and an added substance called Montanide that helps the immune system respond to the vaccine. Sargramostim, another substances that boosts the immune response, is also given.

Patients 18 to 85 years of age with MDS, AML, ALL or CML may be eligible for this study. Candidates are screened with a medical history, physical examination, blood tests, chest x-ray and bone marrow biopsy. Women of childbearing age also have a pregnancy test.

Participants undergo the following:

• Chemotherapy entering the study.

• Leukapheresis to collect large amounts of white blood cells for infusion before vaccine administration.

• Participants may need placement of a central line (plastic tube, or catheter) in the upper part of the chest to be used for giving chemotherapy, blood or platelet transfusions, antibiotics and white blood cells, and for collecting blood samples.

• Weekly vaccine injections for nine weeks, given in the upper arm, upper leg or abdomen.

• Sargramostim injections following each vaccination.

• Standard of care treatment for MDS, AML, ALL or CML, which may include blood or platelet transfusions, growth factors, and drugs to control underlying disease and potential side effects of the vaccine.

• Weekly safety monitoring, including vital signs check, brief health assessment, blood tests and observation after the vaccination, on the day of each vaccination.

• Follow-up evaluations with blood tests and chest x-ray 3 weeks after the last vaccine dose and with blood tests and bone marrow biopsy 7 weeks after the last vaccine dose.

Condition or Disease	Intervention/Treatment	Phase
Myelodysplastic Syndrome; Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML)	Drug: WT1 Peptide Vaccine	Phase 2

Detailed Description

Leukemias and the related disorders myelodysplastic syndrome and myeloproliferative diseases represent a wide group of bone marrow stem cell malignancies. Some patients can be cured with chemotherapy or by allogeneic stem cell transplantation. However, standard treatment approaches are not effective for patients who become refractory to chemotherapy, those who relapse after transplantation and those with progressive disease. The management of such patients remains unsatisfactory and requires new treatment approaches other than chemotherapy.

The immunological graft-versus-leukemia (GVL) effect seen after allogeneic stem cell transplantation suggests that stimulating the patient's own T cell responses to hematological malignancies might also retard disease progression and even achieve disease remissions. Wilm's Tumor 1 (WT1) was identified as a target vaccine antigen because this antigen is over-expressed by cluster of differentiation 34 (CD34) plus stem cells of most patients with myeloid and lymphoid malignancies but not by normal marrow cells. A human leukocyte antigen (HLA-A0201) restricted peptide derived from the Wilm's Tumor (WT) protein is anticipated to induce T cell response against MDS and leukemic cells while sparing normal cells. Of note, about 40% of the population is HLA-A0201 positive.

Therefore we propose this Phase II trial, the second in a series of planned peptide vaccine research, which will evaluate the safety associated with an immunotherapy approach of lymphodepletion, lymphocyte infusion, and WT1 vaccination in select patients diagnosed with MDS, AML, ALL and CML. The WT1 vaccination will comprise of 9 doses of WT-1 peptide vaccines (in Montanide adjuvant) administered concomitantly with granulocyte macrophage- colony stimulating factor (GM-CSF) (Sargramostim).

The primary objectives will be to evaluate the efficacy and toxicity associated with the immunotherapy approach of lymphodepletion, lymphocyte infusion, and WT1 vaccination in selected patients with hematological malignancies.

Secondary objectives will include evaluation of disease response by following the numbers of WT1 expressing cells in blood, hematological measurements (reduction in marrow blast cells, changes in blood counts), transfusion dependence, and time to disease progression and survival.

The primary endpoint will be the side effects of treatment (toxicity and number of circulating WT1 specific T cells (efficacy ) measured through week 16 of the study (7 weeks after the last dose of vaccine).

Study Design

• Study Type: Interventional
• Actual Enrollment: 4 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies
• Study Start Date: Feb 1, 2007
• Actual Primary Completion Date: Nov 1, 2009
• Actual Study Completion Date: Nov 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
Experimental: WT1 Peptide Vaccine WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)	Drug: WT1 Peptide Vaccine; WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim); Other Names: Wilm's tumor 1 vaccine

Outcome Measures

Primary Outcome Measures

1. Cellular Immune Response [7 weeks after last dose of vaccine]

   Minimum criterion for a cellular immune response was defined as the emergence of detectable T cell frequency against Willm's tumor 1 (WT1) when the pre-study analysis found no response, or a twofold increase in T cell frequency at any post vaccination time point

Secondary Outcome Measures

1. Disease Response [7 weeks after last dose of vaccine]

   Clinical response of underlying malignancy to the vaccination

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 85 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

• INCLUSION CRITERIA:

1. Diagnosed with

refractory anemia with excess of blasts (MDS-RAEB).

or

refractory anemia with excess of blasts in transformation (MDS-RAEBt).

or

secondary acute myelogenous leukemia (AML).

or

relapsed or refractory acute or chronic myelogenous leukemias (AML).

or

relapsed or refractory chronic myelogenous leukemias (CML) with accelerated phase or blast crisis

or

relapsed or refractory acute lymphoblastic leukemia (high risk ALL).

or

acute lymphoblastic leukemia (ALL) in complete remission.

or

chronic myelomonocytic leukemia (CMML).

1. Unsuitable for stem cell transplantation (age over sixty or unavailability of a fully-matched donor).

or

made an informed decision not to undergo the transplant procedure.

or

relapsed AML, CML, MDS or ALL post stem cell transplantation (SCT).

1. HLA-A0201 positive.

2. Ages 18 - 85 years.

3. Off all lympho-ablative chemotherapeutic agents.

4. All subjects (men and women) must agree to practice abstinence or effective contraception during the study period.

Inclusion Criteria Donor (for post transplant subjects without available donor lymphocyte infusion (DLI) cells):

1. Related donor, HLA identical (6/6) with recipient.

2. Age greater than or equal to 18 or less than or equal to 80 years old.

3. Ability to comprehend the investigational nature of the study and provide informed consent.

EXCLUSION CRITERIA:

1. HIV positive (HIV-infected patients are immune-compromised and it is unlikely that these patients will be capable of mounting an immune response to the vaccine).

2. Treatment with systemic corticosteroids within 7 days prior to study entry.

3. Low bone marrow reserves (less than 20 percent cellularity).

4. Serum creatinine greater than 2.5mg/dl or serum bilirubin greater than 4mg/dl (patients receiving fludarabine).

5. Co-morbidity of such severity that it would preclude the patient's ability to tolerate protocol therapy.

6. Predicted survival less than 3 months.

7. Previous allergic reaction to Montanide Adjuvant.

8. Pregnant or breast feeding (Pregnant and breast-feeding women are excluded from study because the effects of vaccination are not known and may pose a risk to the developing fetus. All female patients will have a urine pregnancy test, and only those that test negative will be allowed on study).

9. Enrolled in another vaccine clinical trial during the study period.

10. Inability to comprehend the investigational nature of the study and provide informed consent.

Exclusion Criteria-Donor (any of the following):

1. Pregnant or lactating.

2. Unfit to receive filgrastim (G-CSF) and undergo apheresis (abnormal blood counts, history of stroke, uncontrolled hypertension).

3. HIV positive.

4. Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the bone marrow transplant (BMT) treatment unlikely and making informed consent impossible.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National Cancer Institute (NCI), 9000 Rockville Pike	Bethesda	Maryland	United States	20892

Sponsors and Collaborators

• National Heart, Lung, and Blood Institute (NHLBI)

Investigators

• Principal Investigator: John Barrett, MD, National Institutes of Health- NHLBI

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• NIH Clinical Center Detailed Web Page

Publications

• Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42. Epub 2007 Sep 17.

• Responsible Party: Minoo Battiwalla, M.D., Principal Investigator, National Heart, Lung, and Blood Institute (NHLBI)
• ClinicalTrials.gov Identifier: NCT00433745
• Other Study ID Numbers: 070091; 07-H-0091; NCT00458965
• First Posted: Feb 12, 2007
• Last Update Posted: Jul 8, 2014
• Last Verified: Jun 1, 2014

• Keywords provided by Minoo Battiwalla, M.D., Principal Investigator, National Heart, Lung, and Blood Institute (NHLBI): Myelodysplastic Syndrome (MDS); Acute Myelogenous Leukemia (AML); Chronic Myelogenous Leukemia (CML); Acute Lymphoblastic Leukemia (ALL); Wilm's Tumor-1 Peptide; Leukemia; Myelodysplastic Syndrome; MDS; Acute Myelogenous Leukemia; AML; Chronic Myelogenous Leukemia; CML; Acute Lymphoblastic Leukemia; ALL
• Additional relevant MeSH terms: Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Wilms Tumor; Myelodysplastic Syndromes; Syndrome; Vaccines

Study Results

Participant Flow

Arm/Group Title	WT1 Peptide Vaccine
Arm/Group Description	Subjects with hematologic malignancies will receive WT1 peptide vaccine to evaluate if the intervention will stimulate a protective immune response.
Period Title: Overall Study
STARTED	4
COMPLETED	4
NOT COMPLETED	0

Baseline Characteristics

Arm/Group Title	WT1 Peptide Vaccine
Arm/Group Description	Subjects with hematologic malignancies will receive WT1 peptide vaccine to evaluate if the intervention will stimulate a protective immune response.
Overall Participants	4
Age (Count of Participants)
<=18 years	0 0%
Between 18 and 65 years	3 75%
>=65 years	1 25%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	54 (18)
Sex: Female, Male (Count of Participants)
Female	3 75%
Male	1 25%
Region of Enrollment (participants) [Number]
United States	4 100%

Outcome Measures

1. Primary Outcome

Title	Cellular Immune Response
Description	Minimum criterion for a cellular immune response was defined as the emergence of detectable T cell frequency against Willm's tumor 1 (WT1) when the pre-study analysis found no response, or a twofold increase in T cell frequency at any post vaccination time point
Time Frame	7 weeks after last dose of vaccine

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	WT1 Peptide Vaccine
Arm/Group Description	Subjects with hematologic malignancies will receive WT1 peptide vaccine to evaluate if the intervention will stimulate a protective immune response.
Measure Participants	4
Number [participants]	4 100%

2. Secondary Outcome

Title	Disease Response
Description	Clinical response of underlying malignancy to the vaccination
Time Frame	7 weeks after last dose of vaccine

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	WT1 Peptide Vaccine
Arm/Group Description	All 4 patients who were accrued went on to receive the vaccine. Complete Response (CR): defined as an absolute neutrophil count of ≥500/µL, platelet count of ≥75,000/µL, no leukemic blasts in the blood nor evidence of extramedullary leukemia, bone marrow (BM) with a cellularity of more than 20%, maturation of all three cell lineages, no Auer rods, and less than 5% bone marrow blast cells. Partial response (PR): 50% reduction in marrow blasts, with an absolute neutrophil count (ANC) greater than 500/µL, and platelet count greater than 75000/µL. No response: subjects who did not meet the above response criteria were defined as non-responders.
Measure Participants	4
Complete response	0 0%
Partial response	1 25%
No response	3 75%

Adverse Events

Arm/Group Title	WT1 Peptide Vaccine
Arm/Group Description	All 4 patients who were accrued went on to receive the vaccine
All Cause Mortality
	WT1 Peptide Vaccine
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	WT1 Peptide Vaccine
	Affected / at Risk (%)	# Events
Total	0/4 (0%)
Other (Not Including Serious) Adverse Events
	WT1 Peptide Vaccine
	Affected / at Risk (%)	# Events
Total	0/4 (0%)

Limitations/Caveats

Although there was one partial response at 7 weeks, this patient went on to relapse as well. Consequently, all 4 patients had rapid relapses despite vaccination. Accrual was stopped at 4.

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.